FindTrial
Sign In

DTRM-555

DRUG2 trials

Sponsors

Zhejiang DTRM Biopharma

Conditions

B-Cell LymphomaChronic Lymphocytic LeukemiaDiffuse Large B Cell LymphomaFollicular LymphomaRefractory Chronic Lymphocytic LeukemiaRelapsed Chronic Lymphocytic LeukemiaRichter's Transformation

Phase 1

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
CompletedNCT02900716
Zhejiang DTRM BiopharmaB-Cell Lymphoma, Chronic Lymphocytic Leukemia
Start: 2016-09-30End: 2020-11-23Updated: 2020-11-27

Phase 2

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
TerminatedNCT04305444
Zhejiang DTRM BiopharmaDiffuse Large B Cell Lymphoma, Follicular Lymphoma, Refractory Chronic Lymphocytic Leukemia +2
Start: 2020-04-24End: 2024-12-31Updated: 2025-01-08

Related Papers

A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma
Blood2020-11-0413 citations
A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas
Blood2019-11-139 citations
Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality
Blood2018-11-292 citations
A phase Ia/Ib study of a novel BTK inhibitor, DTRMWXHS-12 (DTRM-12), and combination products, with everolimus and pomalidomide, in pts with CLL or other B-cell lymphomas.
Journal of Clinical Oncology2017-05-202 citations